Evaluating oral pouches requires balancing the clear benefits of eliminating combustion against the hidden mechanics of potent chemical dependency. The table below outlines how Zyn measures up against legacy alternatives across exposure profiles, delivery mechanisms, and primary biological risks.
| Product Type | Active Nicotine Delivery | Combustion / Aerosol Exposure | Primary Physical Health Risks |
|---|---|---|---|
| Zyn Pouches | Oral mucosal absorption (3mg, 6mg per pouch) | None; spit-free oral packet | Gum recession, mucosal irritation, elevated heart rate, acute chemical dependence |
| Disposable Vapes (E-Cigarettes) | Pulmonary aerosol inhalation (20mg, 50mg/mL salts) | Heavy vapor containing propylene glycol, vegetable glycerin, volatile organic compounds | Bronchial inflammation, wheezing, vascular stiffness, heavy dependence |
| Combustible Cigarettes | Pulmonary smoke inhalation (~1mg, 1.5mg absorbed per stick) | Full combustion generating tar, carbon monoxide, and 70+ known carcinogens | Lung cancer, emphysema, coronary heart disease, stroke, systemic organ damage |
| Traditional Dip & Snus | Oral mucosal absorption from cured tobacco leaves | None; spit-dependent for American dip, non-spit for pasteurized snus | Leukoplakia, esophageal and pancreatic cancer risks, severe gum recession, tooth decay |
